[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597547":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":10,"centralContacts":10,"locations":10,"responsibleParty":34,"collaborators":10,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":42,"acronym":10,"eligibilityCriteria":43,"healthyVolunteers":40,"sex":44,"minAge":45,"maxAge":10,"enrollmentInfo":46,"targetDuration":10,"studyType":49,"phases":10,"briefSummary":50,"conditions":51,"keywords":10,"overallStatus":54,"whyStopped":10,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":10},{"fullName":5,"class":6},"Assiut University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients known ITP",null,"Patients known ITP either newly diagnosed, chronic, refractory Age 18 yrs and above Patients with thyrodiectomy will not be in our study",[13,14,15],"Diagnostic Test: Search for thyroid disorders","Diagnostic Test: Laboratory test","Drug: Steroid and eltrombopage",[17,24,27],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"DIAGNOSTIC_TEST","Search for thyroid disorders","TSH , FT3 , FT4",[9],[23],"Laboratory test",{"type":18,"name":23,"description":25,"armGroupLabels":26,"otherNames":10},"Search for anti thyroid antibodies",[9],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DRUG","Steroid and eltrombopage","See when we treat thyroid disorders, will patient respond to steroid or eltrombopage?",[9],[33],"Drugs used in ITP",{"type":35,"investigatorFullName":36,"investigatorTitle":37,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Ayah Ibrahim Nemr","Assiut","100597547","prevalence-of-thyroid-disorders-in-patients-with-immune-thrombocytopenic-purpura-and-its-impact-on-treatment-100597547",false,"NCT07059910","Prevalence of Thyroid Disorders in Patients With Immune Thrombocytopenic Purpura and Its Impact on Treatment","Inclusion Criteria:\n\n* ITP patients will be classified as newly diagnosed, persistent and chronic based on duration less than 3 months, 3-12 months, and more than 12 months respectively.\n\n  * refractory ITP patients.\n\nExclusion Criteria:\n\n* patients with history of thyroidectomy\n\n  * patients with history of drug induced ITP\n  * patients with history of HCV, HBV and HIV infection.\n  * Patients who refuse to contribute in this study.","ALL","18 Years",{"count":47,"type":48},100,"ESTIMATED","OBSERVATIONAL","Prevalence of thyroid disorders in patients with immune thrombocytopenic purpura and its impact on treatment",[52,53],"Immune Thrombocytopenic Purpura","Thyroid Disorders","NOT_YET_RECRUITING","2025-07-13",{"date":57,"type":58},"2025-07-17","ACTUAL",{"date":60,"type":48},"2025-07",{"date":62,"type":48},"2026-08-15",{"name":5,"class":6}]